Alzheimer Disease, Early Onset
Conditions
Keywords
Alzheimer's disease, Gamma activity, Resting-state EEG, Discriminative power, MRI
Brief summary
The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.
Detailed description
This cross-sectional study included 24 drug-naive CSF-proven EOAD patients and age-, sex, and education-matched healthy controls. All participants underwent a detailed neuropsychological evaluation, resting-state electroencephalography (EEG) recording, and Magnetic Resonance Imaging (MRI). Gamma power and coherence were measured in total gamma (30-48 Hz), gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz) frequency bands. Gray matter volumes were extracted for 54 regions of interest (ROIs) and compared between groups. Discriminant analysis was performed to determine the classification accuracy of gamma activity for EOAD. Finally, correlations between CSF, neuropsychological tests, EEG, and MRI measures were explored.
Interventions
DIAGNOSTIC_TESTCSF
Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
Sponsors
Görsev Yener, MD, PhD
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* For all participants: Age \< 65 * For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria. * For healthy controls: Mini-Mental State Examination (MMSE) \>25 Instrumental Activities of Daily Living Scale (IADL) = 8
Exclusion criteria
* For EOAD patients: MMSE \> 24 Geriatric depression scale (GDS) \> 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities. * For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS \> 14 * For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EEG | Day 2 | The resting state EEG recordings were acquired using Easy-Cap comprising 30 Ag/AgCl electrodes placed according to the international 10-20 system. Coherence and maximum peak power of the total gamma (30-48 Hz) and sub-gamma bands \[gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz)\] were measured for each participant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation Analysis | 3 months | Correlations between CSF, neuropsychological tests (NPT), EEG, and MRI measures were investigated. |
| Discriminant Analysis | 3 months | The discriminative power of gamma measures (power and coherence) was investigated with discriminant analysis (DA). |
| MRI | Day 1 | Participants underwent structural magnetic resonance imaging on a Philips Achieva 1.5 Tesla scanner. The gray matter volumes were obtained from the 3D-T1 weighted Turbo field echo (TFE) sequence (TR: 9ms, Time to Echo (TE): 4ms, Field-of-view (FOV): 240mm, matrix: 256, slice thickness: 1mm, numbers of signal averages (NSA): 1). The images were segmented into gray matter, white matter, and CSF with the default parameters of the CAT12 segmentation function. Only the gray matter calculations were compared between groups. |
Countries
Turkey (Türkiye)
Outcome results
None listed